Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 36 of 151 for:    Ipratropium OR atrovent

Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02172781
Recruitment Status : Completed
First Posted : June 24, 2014
Last Update Posted : June 24, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment

Condition or disease Intervention/treatment Phase
Healthy Drug: Ipratropium - unit dose vial Drug: Tiotropium - inhalation capsule Drug: Placebo matching tiotropium Drug: Placebo matching ipratropium Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-blind, Randomised, Two-way Cross-over Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects of a Single Additional Dose of 500 µg Ipratropium Bromide Unit Dose Vial Inhaled Via Nebuliser Versus Placebo After 19 Days of Treatment With Tiotropium Inhalation Capsules 18 µg q.d. in Male Healthy Volunteers.
Study Start Date : January 2001
Actual Primary Completion Date : April 2001

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Ipratropium - unit dose vial Drug: Ipratropium - unit dose vial
Drug: Placebo matching ipratropium
Experimental: Tiotropium - inhalation capsule - low dose Drug: Ipratropium - unit dose vial
Drug: Tiotropium - inhalation capsule
Drug: Placebo matching tiotropium
Drug: Placebo matching ipratropium
Placebo Comparator: Placebo matching tiotropium - inhalation capsule Drug: Ipratropium - unit dose vial
Drug: Tiotropium - inhalation capsule
Drug: Placebo matching tiotropium
Drug: Placebo matching ipratropium
Placebo Comparator: Placebo matching to ipratropium - unit dose vial Drug: Ipratropium - unit dose vial
Drug: Tiotropium - inhalation capsule
Drug: Placebo matching tiotropium
Drug: Placebo matching ipratropium
Experimental: Tiotropium - inhalation capsule - high dose Drug: Ipratropium - unit dose vial
Drug: Tiotropium - inhalation capsule
Drug: Placebo matching ipratropium



Primary Outcome Measures :
  1. AUC - Area under the curve of the log-transformed value of salivary secretion after application of randomised treatment [ Time Frame: over the interval from two hours to six hours on study day 19 and 22 ]

Secondary Outcome Measures :
  1. Cmax (Peak (maximum) plasma concentration) - Tiotropium [ Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) ]
  2. Cmax,ss (maximum observed concentration of the analyte in plasma at steady state) - Tiotropium [ Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) ]
  3. Tmax (time to reach the peak plasma concentration) - Tiotropium [ Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) ]
  4. Tmax, ss (Time to reach maximum concentration of the analyte in plasma at steady state) - Tiotropium [ Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) ]
  5. Cpre (predose concentration of the analyte in plasma) -Tiotropium [ Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) ]
  6. Cpre,ss (predose concentration of the analyte in plasma at steady state) - Tiotropium [ Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) ]
  7. AUC (area under the concentration time curve of the analyte in plasma) - Tiotropium [ Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) ]
  8. AUC,ss (area under the concentration time curve of the analyte in plasma at steady state) - Tiotropium [ Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) ]
  9. Ae (amount of analyte that is eliminated in urine) - Tiotropium [ Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) ]
  10. CLR (renal clearance of the analyte) - Tiotropium [ Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) ]
  11. Cmax (Peak (maximum) plasma concentration) - Ipratropium [ Time Frame: Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing) ]
  12. Tmax (time to reach the peak plasma concentration) - Ipratropium [ Time Frame: Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing) ]
  13. AUC (area under the concentration time curve of the analyte in plasma) - Ipratropium [ Time Frame: Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing) ]
  14. Ae (amount of analyte that is eliminated in urine) - Ipratropium [ Time Frame: Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing) ]
  15. CLR (renal clearance of the analyte) - Ipratropium [ Time Frame: Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing) ]
  16. Amount of Salivary secretion [ Time Frame: Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23 ]
  17. FEV1 (Forced expiratory volume in one second) [ Time Frame: Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23 ]
  18. FVC (Forced vital capacity) [ Time Frame: Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23 ]
  19. MMEF25-75% (maximal mid-expiratory flow) [ Time Frame: Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23 ]
  20. PEFR (peak expiratory flow rate) [ Time Frame: Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23 ]
  21. Occurence of adverse events [ Time Frame: Screening, A1-A6, B1-B23, end of study (within 8 days after last dosing tiotropium) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All participants in the study should be healthy males, ranging from 40 to 65 years of age and within ±20% of their normal weight (Broca-Index)

Each subject will have his medical history taken and will receive a complete medical examination (including blood pressure and pulse rate measurements) as well as a 12-lead ECG.

Haematological, hepatic and renal function tests will be carried out in the laboratory (Bioscentia GmbH, FRG). The subjects will fast for 8 hours before collection of specimens for all laboratory evaluations. The above mentioned examinations will be performed within 14 days before the first drug administration.

In accordance with Good Clinical Practice (GCP) and local legislation all subjects will have given their written informed consent prior to admission to the study.

Following inclusion criteria were of special interest for this study:

  • Normal spirometry as evidenced by a baseline FEV1 ≥ 80% of predicted normal value for age, height and sex. Predicted normal values will be calculated according to European Community of Coal and Steel (ECCS)
  • Ability to perform technically satisfactory pulmonary function tests.

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance.
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
  • History of orthostatic hypotension, fainting spells or blackouts.
  • Chronic or relevant acute infections.
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator.
  • Intake of drugs with a long half-life (≥ 24hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study.
  • Use of any drugs which might influence the results of the trial up to seven days prior to enrolment in the study or during the study, among these all non-selective beta blockers, oral beta adrenergics or long-acting beta-adrenergics such as salmeterol and formoterol, and anticholinergic drugs including ATROVENT ®(ipratropium) by oral inhalation and ATROVENT® Nasal Spray.
  • Participation in another trial with an investigational drug (≤ two months prior to administration or during trial).
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on trial days.
  • Alcohol abuse (> 60g/day)
  • Drug abuse
  • Blood donation (≥ 100 ml within four weeks prior to administration or during the trial)
  • Any laboratory value outside the clinically accepted reference range.
  • Excessive physical activities (within the last week before and during the study)

Following exclusion criteria are of special interest for the study:

  • Subjects with known hypersensitivity to anticholinergic drugs.
  • Subjects with known symptomatic prostatic hypertrophy or bladder neck obstruction
  • Subjects with known narrow-angle glaucoma

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02172781     History of Changes
Other Study ID Numbers: 205.239
First Posted: June 24, 2014    Key Record Dates
Last Update Posted: June 24, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Ipratropium
Tiotropium Bromide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action